Comparative cost-effectiveness models for the treatment of multiple myeloma
Comparative cost-effectiveness models for the treatment of multiple myeloma
Objectives: To compare cost effectiveness models for the first-line treatment of multiple myeloma, and explore the differences between the models’ structure, parameters, assumptions and results.
Methods: Three cost effectiveness models for the treatment of multiple myeloma, were compared that had been developed to inform resource allocation in the UK for the chemotherapy regimens bortezomib, melphalan and prednisolone (BMP); and melphalan, prednisolone and thalidomide (MPT) versus melphalan and prednisolone (MP). The models used alternative approaches and assumptions to estimate the overall survival and progression-free survival for each of the interventions. Through the use of sensitivity analyses, the most influential parameters and assumptions of each of the models were identified.
Results: The models developed by the manufacturers gave conflicting results, with each manufacturer favouring their drug. The differences between the model results were determined by two parameters: the hazard ratio for overall survival for MPT vs. MP and the cost of bortezomib.
Conclusions: Using models developed for assessing treatments for multiple myeloma we demonstrated that it was feasible to compare models, which then aided decision makers in making reimbursement decisions.
cost-utility analysis, thalidomide, bortezomib, multiple myeloma
1-8
Cooper, K.
6b37f95e-daae-4b87-9f79-0fabd4eb8f6b
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Cooper, K.
6b37f95e-daae-4b87-9f79-0fabd4eb8f6b
Picot, J.
324d6f20-a105-49fd-9fb0-88791be84ada
Bryant, J.
508f497c-8b5a-468f-a37d-be9c26e4e49d
Clegg, A.
838091f5-39df-4dbe-a369-675b26f2301b
Cooper, K., Picot, J., Bryant, J. and Clegg, A.
(2014)
Comparative cost-effectiveness models for the treatment of multiple myeloma.
International Journal of Technology Assessment in Health Care, .
(doi:10.1017/S0266462313000615).
(PMID:24451119)
Abstract
Objectives: To compare cost effectiveness models for the first-line treatment of multiple myeloma, and explore the differences between the models’ structure, parameters, assumptions and results.
Methods: Three cost effectiveness models for the treatment of multiple myeloma, were compared that had been developed to inform resource allocation in the UK for the chemotherapy regimens bortezomib, melphalan and prednisolone (BMP); and melphalan, prednisolone and thalidomide (MPT) versus melphalan and prednisolone (MP). The models used alternative approaches and assumptions to estimate the overall survival and progression-free survival for each of the interventions. Through the use of sensitivity analyses, the most influential parameters and assumptions of each of the models were identified.
Results: The models developed by the manufacturers gave conflicting results, with each manufacturer favouring their drug. The differences between the model results were determined by two parameters: the hazard ratio for overall survival for MPT vs. MP and the cost of bortezomib.
Conclusions: Using models developed for assessing treatments for multiple myeloma we demonstrated that it was feasible to compare models, which then aided decision makers in making reimbursement decisions.
This record has no associated files available for download.
More information
e-pub ahead of print date: 22 January 2014
Keywords:
cost-utility analysis, thalidomide, bortezomib, multiple myeloma
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 361727
URI: http://eprints.soton.ac.uk/id/eprint/361727
ISSN: 0266-4623
PURE UUID: 95899bd6-e767-4804-87ed-2f859f8b2f39
Catalogue record
Date deposited: 31 Jan 2014 15:04
Last modified: 15 Mar 2024 03:19
Export record
Altmetrics
Contributors
Author:
K. Cooper
Author:
J. Bryant
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics